格隆汇3月17日丨领航医药生物科技(00399.HK)公告，于2025年3月15日，公司的非全资附属公司福仕生物工程有限公司与Terry Bio Pharmaceutical Co.,Ltd.（作为代理）订立代理协议，据此，订约方同意在代理协议的条件达成后第三个营业日起计6年期间，代理将作为附属公司的独家代理，在泰国推销、分销、销售及推广代理协议内订明的附属公司的口服胰脏保健产品。
代理为一间于泰国注册成立的有限公司，主要从事销售医药中间体、保健产品及食品。董事会相信，与代理订立代理协议将有利于集团口服胰脏保健产品的销售及分销在泰国新市场的发展。订立代理协议展现集团为实现寻找与合适合作伙伴合作，以提升股东回报及集团整体可持续长期发展所作的积极努力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.